| Literature DB >> 31662099 |
Sofia J Araújo1,2, Isao Kuraoka3.
Abstract
Nucleotide excision repair (NER) is a highly conserved mechanism to remove helix-distorting DNA lesions. A major substrate for NER is DNA damage caused by environmental genotoxins, most notably ultraviolet radiation. Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy are three human disorders caused by inherited defects in NER. The symptoms and severity of these diseases vary dramatically, ranging from profound developmental delay to cancer predisposition and accelerated ageing. All three syndromes include developmental abnormalities, indicating an important role for optimal transcription and for NER in protecting against spontaneous DNA damage during embryonic development. Here, we review the current knowledge on genes that function in NER that also affect embryonic development, in particular the development of a fully functional nervous system.Entities:
Keywords: Cockayne syndrome; central nervous system; development; embryo; nucleotide excision repair; xeroderma pigmentosum
Mesh:
Substances:
Year: 2019 PMID: 31662099 PMCID: PMC6833223 DOI: 10.1098/rsob.190166
Source DB: PubMed Journal: Open Biol ISSN: 2046-2441 Impact factor: 6.411
Figure 1.Schematic diagram of NER proteins involved in NER (TC-NER and GG-NER) and other pathways. (a) Schematic of the protein complexes involved in NER. Different recognition complexes operate during TC-NER and GG-NER. After the damage recognition step, the same protein complex is involved in damage excision and repair. NER factors also participate in replication (b), transcription (c) and other DNA repair pathways (d).
Known embryonic transcript expression of NER transcripts in Mus musculus according to the Gene eXpression Database (GXD; http://www.informatics.jax.org/expression.shtml) and Drosophila melanogaster according to the Berkeley Drosophila Genome Project (BDGP; https://insitu.fruitfly.org). ND, not identified in this species; GUDMAP, GenitoUrinary Development Molecular Anatomy Project.
| mouse gene | embryonic expression | reference | embryonic expression | reference | |
|---|---|---|---|---|---|
| limb bud | [ | ventral nerve cord | [ | ||
| ubiquitous; nervous system and liver | [ | ubiquitous | [ | ||
| no expression data | — | faint ubiquitous | [ | ||
| nervous system, eye and liver | [ | ubiquitous (nuclear) | [ | ||
| nervous system | [ | no available data | — | ||
| nervous system | [ | no available data | — | ||
| nervous system | [ | no available data | — | ||
| nervous system; genitourinary system | [ | faint ubiquitous | [ | ||
| cranium | [ | CSA (ND) | — | — | |
| genitourinary system | GUDMAP | CSB (ND) | — | — | |
| nervous system | [ | ubiquitous | [ |
Figure 2.Embryonic and nervous system (NS) expression of NER genes in Drosophila melanogaster and Mus musculus. Graphical representation of transcript expression during embryonic development, according to high-throughput expression data. (a) D. melanogaster expression data from ModENCODE (www.modencode.org) tissue and temporal expression data; (b) M. musculus expression data from Expression Atlas (www.ebi.ac.uk/gxa/home) embryonic and tissue expression data. Data mining was performed according to all developmental stages (embryonic expression) and specific nervous system expression (larval expression for Drosophila and embryonic expression for mouse). Arbitrary values were attributed according to expression levels (1, low; 2, moderate; and 3, high) and plotted in parallel.
Requirements of NER genes during development inferred by the analysis of null mutations in Mus musculus and Drosophila melanogaster.
| mouse gene | phenotype | phenotype | reference | |
|---|---|---|---|---|
| viable; develop normally | no mutant developmental data | [ | ||
| embryonic lethal | embryonic lethal; CNS defects | [ | ||
| viable; develop normally | no mutant developmental data | [ | ||
| pre-implantation lethality | embryonic lethal; early mitotic division defects | [ | ||
| mice are viable but die before weaning | no mutant developmental data | [ | ||
| viable but growth failure and death before weaning | no mutant developmental data | [ | ||
| severe postnatal growth defect with death approximately three weeks after birth | no mutant developmental data | [ | ||
| impaired embryonic development; prenatal and early postnatal death (90%) | no mutant developmental data | [ | ||
| viable; minor postnatal growth retardation and neurological defects | not identified | — | [ | |
| viable; minor postnatal growth retardation and neurological defects | not identified | — | [ | |
| embryonic lethal | embryonic lethal; organogenesis defects | [ |